Latest Articlesddd
FDA Lifts Partial Clinical Hold on Gilead Sciences Studies of Magrolimab On April 12, 2022, Gilead …
The Clinical Stage Biotech Firms We have reasons to believe that some clinical-stage biotechnology firms, …
Jazz Pharmaceuticals and Werewolf Therapeutics Agreement Jazz Pharmaceuticals (JAZZ) and Werewolf Therapeutics (HOWL)
Sunshine Biopharma mRNA Therapeutics Effective at Destroying Cancer Cells Sunshine Biopharma, Inc. (SBFM) – a pharmaceutical …
Gilead Sciences' Product Yescarta Kite - a Gilead Sciences (GILD) Company, announced the U.S. FDA has approved …
Reata Pharmaceuticals Completed Rolling NDA Submission for Omaveloxolone for Friedreich’s Ataxia Reata Pharmaceuticals (RETA) announced the …
Vertex Pharmaceuticals Statistically Significant Results From Vertex VX-548 for Acute Pain Vertex Pharmaceuticals (VRTX) announced positive …
Our Most Pressing Need Our current, most pressing need is news that makes sense. Stock Market …
Comprehensive Prohost Letter Issues Reality The Best of words in informative texts are the smallest in …
Some Gains in Biotech Stocks During the War in Europe On Tuesday, Mar 8,2022 the United …
Intellia Therapeutics Statement on Recent U.S. Patent and Trademark Office Decision – In May 2012, the …
The circumstances that we find the world in today are abnormal. They are extremely intense and …
Intellia Therapeutics Loses Technology Patent and Suffers a Selloff A selloff of Intellia Therapeutics (NTLA) stock …
The Stock Market Continues to Plummet Indeed, the Stock Market continues to decline, losing investors' profits. …
We do not dare invest in the stock market at a time when almost all the …
Enanta Pharmaceuticals Expectations Expecting Dosing in a First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor …
Regenxbio Good News for wet AMD On January 10, 2022, Regenxbio Inc. (RGNX) announced the initiation of …
Intellia Therapeutics Acquires Rewrite Therapeutics The acquisition is, indeed good news. By acquiring Rewrite Therapeutics, Intellia …
The Stock Market Today Before the end of 2021 we recognized that investors were not going …
We Are Back! Thanks to God. Hello to all our subscribers. Our sickness was unanticipated, making …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
